Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
暂无分享,去创建一个
N. Lennon | A. Giobbie-Hurder | R. Mak | Catherine J. Wu | Helen X. Chen | F. Hodi | Carrie Lee | S. Rodig | J. Abbruzzese | Mansoor M Ahmed | S. Jabbour | R. Gentzler | Junko Tsuji | Jason L. Weirather | S. Arnold | M. Awad | Haeseong Park | J. Schoenfeld | K. Stephans | A. Monjazeb | Lin Yang | E. Sharon | J. Hubbard | H. Streicher | Ana Lako | L. Villaruz | S. Ranasinghe | Katrina Z. Kao | Yang Liu | Ryan C. Brennick | N. Uboha | Jennifer M. Johnson | H. Lyon | Carrie Cibuskis | Aashna Jhaveri | Jennifer Altreuter | Lauren Gunasti | Ryan C Brennick | J. Tsuji | L. Gunasti